Farr M, Scott D G, Bacon P A
Drugs. 1986;32 Suppl 1:49-53. doi: 10.2165/00003495-198600321-00010.
The side effect profile of sulphasalazine was documented in 200 patients with inflammatory joint disease treated with the drug for at least 1 year. Fifty-eight percent of patients developed one or more adverse reactions and in 21.5% the drug was withdrawn. A further 28% continued taking the drug at a reduced dose. Five percent of the side effects were judged to be potentially serious. In all patients the reactions subsided on either discontinuation of the drug or reduction of the dose. Gastrointestinal (33%) and central nervous system reactions (19%) were the most common, but all were relatively minor. Neutropenia (2%), thrombocytopenia (1%) and pan-hypogammaglobulinaemia (1%) were potentially the most serious effects. The side effect profile of sulphasalazine in inflammatory joint disease appeared to be similar to that in inflammatory bowel disease, but reactions were more frequent in inflammatory joint disease. Enteric-coated sulphasalazine is a useful addition to the small number of slow acting antirheumatic drugs, and in view of its established efficacy, its level of toxicity was found to be 'acceptable' as long as patients were carefully monitored and regular blood tests were carried out.
对200例接受柳氮磺胺吡啶治疗至少1年的炎症性关节病患者的副作用情况进行了记录。58%的患者出现了一种或多种不良反应，21.5%的患者停药。另有28%的患者继续以减量服用该药物。5%的副作用被判定为可能严重。在所有患者中，反应在停药或减量后均消退。胃肠道反应（33%）和中枢神经系统反应（19%）最为常见，但均相对较轻。中性粒细胞减少（2%）、血小板减少（1%）和全低丙种球蛋白血症（1%）可能是最严重的影响。柳氮磺胺吡啶在炎症性关节病中的副作用情况似乎与炎症性肠病相似，但在炎症性关节病中反应更频繁。肠溶型柳氮磺胺吡啶是少数慢作用抗风湿药物中的一种有用补充，鉴于其已确立的疗效，只要对患者进行仔细监测并定期进行血液检查，其毒性水平被认为是“可接受的”。
